Adventrx maintained at perform rating by RBC

Adventrx Pharmaceuticals was kept at its sector perform, speculative risk rating by RBC Capital Markets analyst Jason Kantor after the company gave updated data on its phase 2 study of CoFactor. Overall survival mirrored previous results and beat historic controls. Shares of the San Diego-based biopharmaceutical company were down $0.20, or 4.55%, at $4.20 on volume of 359,900 shares versus the three-month running average of 422,652 shares. (Amex: ANX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.